Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10152392 | 0.71 | KDM4E (0.39) | KDM4EGAATHRBRECQLL3MBTL1 | |
| SCHEMBL16001684 | 0.70 | KDM4E (0.32) | KDM4EGAATHRBRECQLL3MBTL1 | |
| SCHEMBL17481248 | 0.64 | LRRK2 (0.30) | — | |
| SCHEMBL13056784 | 0.62 | KDM4E (0.33) | KDM4EGAATHRBRECQLL3MBTL1 | |
| SCHEMBL29712038 | 0.60 | — | — | |
| SCHEMBL2228297 | 0.59 | POLB (0.42) | KDM4EL3MBTL1 | |
| SCHEMBL23952968 | 0.58 | KDM4E (0.30) | KDM4EGAATHRBRECQLL3MBTL1 | |
| SCHEMBL15912312 | 0.58 | KDM4E (0.30) | KDM4EGAATHRBRECQLL3MBTL1 | |
| Pivalamide SCHEMBL2484 | 0.55 | — | — | |
| SCHEMBL7980141 | 0.55 | LMNA (0.46) | KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340532-B2 | Methods and compositions for inhibiting CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150307482-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307482-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | CNKSR1, CAMKK1, CAMKK2 | KDM4E 770/4885GAA 4092/4885THRB 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.